Shanghai
-
Ractigen Launches Phase II Trial for Bladder Cancer Treatment
Ractigen Therapeutics initiates Phase II clinical trial for saRNA therapy RAG-01 to treat non-muscle invasive bladder cancer in China.
Most read
-
Martin Lewis Warns Savers With £10,000 or More They Could Owe Tax on Interest
-
Selangor International Care Expo 2026 Targets the Growing Care Economy
-
Asian & Oceanian Epilepsy Congress 2026 in Kuala Lumpur
-
Baby & Beyond Maternity Expo in Kuala Lumpur 2026
-
Axos Offers 5.00% Savings Rate for Six Months After Fed Hike, With Strings Attached
-
Ractigen Launches Phase II Trial for Bladder Cancer Treatment
-
Blood Cancer UK launches £25m appeal to double leukaemia survival rates
-
MIT Scientists Develop Personalized Cancer Vaccines Using Nanoparticles
-
KEYNOTE-B49 Shows Pembrolizumab Delays Progression in PD-L1-Positive Breast Cancer
-
Flawed Studies Prompt Hormone Therapy Caution for Breast Cancer Survivors
-
Affluent Investors Over 60 Face Tax Risks When Splitting Assets
-
Nicole Eggert’s Cancer Bills and a Trial That Cut Financial Toxicity for Patients
-
Why Retirees Must Shift Emergency Fund Strategies Beyond Standard Three-Month Rules
-
Timekeepers Vote to End Leap Seconds From May 20, 2027, After Years of Software Outages
-
Why Personal Bankruptcies Jumped 11% Despite Economic Growth
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992